A Phase I Dose-Escalation Study of PHA-793887 Administered as a 1 Hour IV infusion for 5 Consecutive Days every 2 weeks or every 3 weeks in Patients with Advanced/Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2007
At a glance
- Drugs PHA 793887 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 20 Nov 2007 New trial record.